Spark Investment Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Spark Investment Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-105,900	Closed	-$2.43M	–	815
2018 Q3	$2.43M	Sell	105,900 -41,400	-28%	-$845K	0.14%	220
2018 Q2	$2.81M	Sell	147,300 -114,900	-44%	-$1.92M	0.16%	182
2018 Q1	$4.42M	Sell	262,200 -121,200	-32%	-$2.03M	0.28%	111
2017 Q4	$5.83M	Buy	383,400 +29,000	+8%	+$430K	0.31%	91
2017 Q3	$6.34M	Buy	354,400 +61,000	+21%	+$1.02M	0.34%	93
2017 Q2	$4.78M	Buy	293,400 +94,900	+48%	+$1.37M	0.3%	104
2017 Q1	$2.78M	Buy	198,500 +150,800	+316%	+$2.15M	0.18%	187
2016 Q4	$760K	Buy	+47,700	New	+$767K	0.06%	393
2016 Q3	–	Sell	-54,400	Closed	-$608K	–	894
2016 Q2	$608K	Buy	+54,400	New	+$527K	0.06%	419
2013 Q3	–	Sell	-115,000	Closed	-$926K	–	592
2013 Q2	$926K	Buy	+115,000	New	+$774K	0.25%	111

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Spark Investment Management's VNDA Position: Q4 2018 in Review

Spark Investment Management sold out of Vanda Pharmaceuticals (VNDA) in Q4 2018, closing a stake of 105,900 shares — an estimated $2.43M sold.

Spark Investment Management first reported a position in VNDA in Q2 2013 and held it in 10 quarters. The position peaked at $6.34M in Q3 2017. 186 funds tracked by Wall St. Rank hold VNDA as of Q4 2018.

Spark Investment Management reported no remaining Vanda Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Spark Investment Management sold 105,900 Vanda Pharmaceuticals shares in Q4 2018, an estimated $2.43M.
Spark Investment Management first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 10 quarters.
Spark Investment Management's Vanda Pharmaceuticals position peaked at $6.34M in Q3 2017.
186 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2018.

Based on Spark Investment Management's 13F filing for Q4 2018, filed 12 Feb 2019.